RIFFAT QURESHI: Open Payments
NPI 1134114416 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,104 in 48 payments from 13 companies in 2025. Trend: 2023 $544 · 2024 $850 · 2025 $1,104
Food & beverage: $1,104
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 8 | $264 |
| ABBVIE INC. | 12 | $201 |
| Otsuka America Pharmaceutical, Inc. | 7 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $77 |
| E.R. Squibb & Sons, L.L.C. | 4 | $75 |
| Neurocrine BioSciences, Inc. | 3 | $70 |
| Lundbeck LLC | 3 | $66 |
| Bausch Health US, LLC | 3 | $54 |
| Corium, LLC | 1 | $34 |
| Alkermes, Inc. | 1 | $30 |
Products named: VRAYLAR, FANAPT, REXULTI, HETLIOZ, ABILIFY ASIMTUFII, CAPLYTA, COBENFY, INGREZZA.
Industry payments across FL — which companies pay providers there.
